Risk factors for mortality in patients with acute kidney injury and hypotension treated with continuous veno-venous hemodiafiltration

In Myung Oh, Jang Han Lee, Kyoung Hwa Yoo, Ji Eun Park, Dong Hyun Oh, Mi Jung Kim, Seung Hea Ha, Gi Jong Lee, Jung Hee Kim, Yoon Chul Jung*

Department of Internal Medicine, Bundang Jesaeng General Hospital, Sungnam, Korea

Abstract

Background: Continuous veno-venous hemodiafiltration (CVVHDF) is a preferred treatment modality in hemodynamically unstable acute kidney injury (AKI) patients, because it has advantages over intermittent dialysis in terms of hemodynamic stability. However, this patient group still shows a significantly high mortality rate. To aid in the management of these high-risk patients, we evaluated the risk factors for mortality in CVVHDF-treated hypotensive AKI patients.

Methods: We studied 67 patients with AKI and hypotension who were treated with CVVHDF from February 2008 to August 2010. We reviewed patient characteristics and laboratory parameters to evaluate the risk factors for 90-day mortality.

Results: Of the 67 enrolled patients (male:female=42:25; mean age=69 ± 14 years), 18 (27%) survived until 90 days after the initiation of CVVHDF. There was no significant difference in survival rates according to the etiology of AKI [hypovolemic shock 2/10 (20%), cardiogenic shock 4/20 (20%), septic shock 12/37 (32%)]. Univariate analysis did show significant differences between survivors and non-survivors in the frequency of ventilator use (44% vs. 76%, respectively; \( P=0.02 \)), APACHE II score (29 ± 7 vs. 34 ± 7, respectively; \( P=0.01 \)), SOFA score (11 ± 4 vs. 13 ± 4, respectively; \( P=0.03 \)), blood pH (7.3 ± 0.1 vs. 7.2 ± 0.1, respectively; \( P=0.03 \)), and rate of urine output < 500 mL for 12 hours (50% vs. 80%, respectively; \( P=0.03 \)). A multivariate Cox proportional hazards model showed that a urine output < 500 mL for 12 hours before the initiation of CVVHDF was the only significant risk factor for 90-day mortality following CVVHDF treatment (odds ratio=2.1, confidence interval=1.01–4.4, \( P=0.048 \)).

Conclusion: A urine output < 500 mL for 12 hours before the initiation of CVVHDF is an independent risk factor for 90-day mortality in hypotensive AKI patients treated with CVVHDF.

© 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Renal replacement therapy (RRT) is required in 5–6% of critically ill patients, and acute kidney injury (AKI) requiring dialysis, is associated with especially high mortality rates of 50–80% [1]. AKI patients requiring RRT also have a high frequency of multiorgan failure or hemodynamic instability [2].

* Corresponding author. Division of Nephrology, Department of Internal Medicine, Bundang Jesaeng General Hospital 255-2 Seohyun-dong, Bundang-gu, Sungnam-si, Gyungki-do 463-774, Korea. E-mail address: j580309@dreamwiz.com (YC Jung).

2211-9132/(S) see front matter © 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.krcp.2012.09.005
Continuous renal replacement therapy (CRRT) was proposed as an alternative to intermittent dialysis in hemodynamically unstable patients, because it is better tolerated, due to the gradual removal of fluid and uremic toxins [3–5].

Although previous studies have identified several prognostic factors for mortality associated with CRRT, such as sepsis, higher APACHE II scores, oliguric AKI, the presence of coma, higher SOFA scores, and the need for mechanical ventilation in critically ill patients undergoing CRRT, each study found different results according to the indication for CRRT and the severity of the disease [6–11]. Therefore, the prognostic factors for patients requiring CRRT still remain somewhat obscure.

Confused classification of patients with regard to the severity and features of their disease, may lead to difficulties in identifying the factors affecting the prognosis of CRRT. Nevertheless, we attempted to assess the characteristics of patients undergoing CRRT treatment. Therefore, this study was focused on AKI patients with hemodynamic instability undergoing CRRT. We evaluated the risk factors for mortality within 90 days after the initiation of CRRT in patients with AKI and hypotension.

**Methods**

**Study population**

The inclusion criteria were a clinical diagnosis of AKI and hypotension. AKI was defined by a twofold increase in serum creatinine, a decrease in estimated glomerular filtration rate (GFR) of >50%, or a reduction in urine output <0.5 mL/kg/hour for 12 hours [12]. Hypotension was defined by an initial mean arterial pressure <60 mmHg, or the use of vasopressors such as dopamine or norepinephrine, to maintain systolic blood pressure >100 mmHg when continuous veno-venous hemodiafiltration (CVVHDF) was started. A total of 108 patients were treated with CVVHDF in the medical-surgical intensive care unit from February 2008 to August 2010. Normotensive patients and those who had end-stage renal disease or malignancy were excluded. We identified 67 patients who had AKI and hypotension at the initiation of CVVHDF. All enrolled patients were followed for >90 days.

**Treatment modality**

CVVHDF was performed with the multiFiltrate (Fresenius Medical Care, Fürth, Germany) and the Ultraflux AV600S dialyzer (surface area = 1.4 m²) (Fresenius Medical Care, St. Wendel, Germany) through double-lumen catheters inserted into the internal jugular or femoral vein. Blood flow rates were maintained between 100 and 150 mL/minute and the predilution replacement method was used. Anticoagulation was performed with heparin or nafamostat.

**Investigated parameters**

Demographic data including age, sex, diabetes mellitus, and hypertension, and clinical parameters such as duration of hospitalization, ventilator use, cause of hypotension, urine output before the initiation of CVVHDF, previous surgical intervention, and type of anticoagulation, were collected. Laboratory parameters, including C-reactive protein, blood urea nitrogen, serum creatinine, white blood cell count, hemoglobin, blood pH and chest radiographic information were also gathered at the initiation of CVVHDF.

SOFA scores and APACHE II scores were employed to evaluate the severity of disease.

Patients were assigned to two groups [RIFLE-I (injury) and RIFLE-F (failure)] with increasing severity of RIFLE stage. We compared demographic, clinical, and laboratory parameters as well as mortality between these two groups.

We also compared demographic, clinical, and laboratory parameters between the survivors and non-survivors to identify the risk factors for mortality in hypotensive AKI patients treated with CVVHDF.

**Statistics**

Data are presented as mean (standard deviation) or median and range. Between-group analyses were made using unpaired Student t tests. Categorical variables were analyzed using the Chi-square test or Fisher’s exact test. Cox regression analysis was used to show the adjusted odds ratio of investigated parameters. Variables with a $P<0.10$ in univariate analyses were included for multivariate analysis. Hazard ratios with their corresponding 95% confidence intervals are reported. A $P<0.05$ was considered statistically significant.

**Results**

**Baseline data and severity of illness**

Basic demographic data are shown in Table 1.

A total of 67 patients were included in this study. The mean age of the patients was 69 ± 14 years, and 42/67 (62%) were male. The most common comorbidity was hypertension (47%), followed by diabetes mellitus (31%). The median length of hospital stay was 13 ± 18 days. Twenty-two out of 67 (32%) patients had undergone surgical intervention within the previous month. Forty-five out of 67 (66%) patients received ventilator care and 36/67 (53%) showed pulmonary edema on chest radiography before the initiation of CVVHDF. Oliguria, defined by a urine output <500 mL within 12 hours before the initiation of CVVHDF, occurred in 48/67 (71%) patients. Thirty-four out of 67 (51%) patients received loop diuretics.

The most common cause of hypotension was septic shock (37/67, 55%), followed by cardiogenic shock (20/67, 30%) and hypovolemic shock (10/67, 15%). The mean APACHE II score was 32 ± 7 and mean SOFA score was 13 ± 4. Mean values for blood urea nitrogen and serum creatinine were 62 ± 34 mg/dL and 3 ± 4 mg/dL, respectively.

In univariate analysis, the rate of oliguria before the initiation of CVVHDF was significantly higher in the RIFLE-F group than in the RIFLE-I group (81% vs. 58%, respectively; $P=0.04$). There was no difference in 90-day mortality between the two groups (73% vs. 73%, respectively; $P=0.99$).

**Outcomes and predictors of survival**

The mortality rate of the hypotensive AKI patients who received CVVHDF was 73% (49/67).

Table 2 shows univariate comparisons of clinical characteristics and laboratory findings between survivors and nonsurvivors.

There were no significant differences in survival rates according to the cause of shock; septic shock (12/37, 32%), cardiogenic shock (4/20, 20%), hypovolemic shock (2/10, 20%).
Table 1. Baseline characteristics of hypotensive acute kidney injury patients treated with continuous veno-venous hemodiafiltration (CVVHDF)

| Demographic characteristics | All patients (n=67) | RIFLE-I (n=26, 39%) | RIFLE-F (n=41, 61%) | P |
|-----------------------------|---------------------|---------------------|---------------------|---|
| Age (y)                     | 69 ± 14             | 66 ± 17             | 71 ± 12             | NS |
| Male, n (%)                 | 42 (62%)            | 16 (62%)            | 26 (62%)            | NS |
| Death, n (%)                | 49 (73%)            | 19 (73%)            | 30 (73%)            | NS |
| Diabetes mellitus, n (%)    | 21 (31%)            | 5 (19.2%)           | 16 (39%)            | NS |
| Hypertension, n (%)         | 32 (47%)            | 11 (42%)            | 21 (51%)            | NS |
| Duration of hospitalization (d) | 13 ± 18         | 13 ± 15             | 14 ± 21             | NS |
| Previous surgical intervention, n (%) | 22 (32%)      | 13 (50%)            | 9 (22%)             | NS |
| Ventilator use, n (%)       | 45 (66%)            | 16 (62%)            | 29 (73%)            | NS |
| Pulmonary edema on chest x-ray, n (%) | 36 (53%)        | 15 (58%)            | 21 (51%)            | NS |
| Urine output < 500 mL for 12 h before initiation of CVVHDF, n (%) | 48 (71%) | 15 (58%) | 33 (81%) | 0.04 |
| Loop diuretic therapy, n (%) | 34 (51%) | 17 (65%) | 17 (41%) | NS |
| Cause of shock              |                     |                     |                     |    |
| Septic shock, n (%)         | 37 (55%)            | 14 (54%)            | 25 (61%)            | NS |
| Cardiogenic shock, n (%)    | 20 (30%)            | 8 (31%)             | 10 (24%)            | NS |
| Hypovolemic shock, n (%)    | 10 (15%)            | 4 (15%)             | 6 (15%)             | NS |
| Anticoagulation             |                     |                     |                     |    |
| Nafamostat, n (%)           | 21 (31%)            | 10 (39%)            | 13 (32%)            | NS |
| Heparin, n (%)              | 26 (39%)            | 9 (35%)             | 17 (42%)            | NS |
| No anticoagulation, n (%)   | 20 (30%)            | 7 (27%)             | 11 (27%)            | NS |
| APACHE II score             | 32 ± 7              | 32 ± 7              | 33 ± 7              | NS |
| SOFA score                  | 13 ± 4              | 14 ± 3              | 12 ± 4              | NS |
| Laboratory findings on initiation of CVVHDF | | | | |
| BUN (mg/dL)                 | 62 ± 34             | 55 ± 31             | 67 ± 35             | NS |
| Serum creatinine (mg/dL)    | 3 ± 4               | 3 ± 1               | 4 ± 4               | 0.02 |
| C-reactive protein (mg/dL)  | 9 ± 7               | 10 ± 8              | 8 ± 7               | NS |
| pH                          | 7.3 ± 0.1           | 7.3 ± 0.1           | 7.2 ± 0.1           | NS |
| WBC (×10^3/mm^3)            | 14,000 ± 7,000      | 16,000 ± 8,000      | 13,000 ± 7,000      | NS |
| Hemoglobin (g/dL)           | 11 ± 2              | 11 ± 2              | 10 ± 3              | NS |
| Platelets (×10^3/mm^3)      | 140 ± 70            | 130 ± 70            | 150 ± 110           | NS |

Table 2. Univariate comparisons of demographic and laboratory findings between survivors and non-survivors in hypotensive acute kidney injury patients treated with continuous veno-venous hemodiafiltration (CVVHDF)

| Demographic characteristics | Survivors (n=18) | Non-survivors (n=49) | P |
|-----------------------------|------------------|----------------------|---|
| Age (y)                     | 65 ± 17          | 70 ± 13              | NS |
| Male, n (%)                 | 12 (67%)         | 30 (63%)             | NS |
| Diabetes mellitus, n (%)    | 7 (39%)          | 14 (29%)             | NS |
| Hypertension, n (%)         | 9 (50%)          | 23 (47%)             | NS |
| Duration of hospitalization (d) | 10 ± 15         | 15 ± 19              | NS |
| Previous surgical intervention, n (%) | 4 (22%)      | 18 (38%)             | NS |
| Ventilator use, n (%)       | 8 (44%)          | 37 (76%)             | 0.02 |
| Pulmonary edema on chest x-ray, n (%) | 6 (33%)        | 30 (61%)             | 0.06 |
| Urine output < 500 mL for 12 h before initiation of CVVHDF, n (%) | 9 (50%) | 39 (80%) | 0.03 |
| Loop diuretic therapy, n (%) | 8 (44%)          | 26 (53%)             | NS |
| Cause of shock              |                   |                      |    |
| Septic shock, n (%)         | 12 (67%)         | 25 (51%)             | NS |
| Cardiogenic shock, n (%)    | 4 (22%)          | 16 (33%)             | NS |
| Hypovolemic shock, n (%)    | 2 (11%)          | 8 (16%)              | NS |
| Anticoagulation             |                   |                      |    |
| Nafamostat, n (%)           | 3 (17%)          | 18 (37%)             | NS |
| Heparin, n (%)              | 6 (33%)          | 20 (41%)             | NS |
| No anticoagulation, n (%)   | 9 (50%)          | 11 (22%)             | NS |
| APACHE II score             | 29 ± 7           | 34 ± 7               | 0.01 |
| SOFA score                  | 11 ± 4           | 13 ± 4               | 0.03 |
| Laboratory findings on initiation of CVVHDF | | | | |
| BUN (mg/dL)                 | 64 ± 31          | 62 ± 35              | NS |
| Creatinine (mg/dL)          | 4 ± 2            | 3 ± 3                | NS |
| C-reactive protein (mg/dL)  | 6 ± 7            | 9 ± 7                | 0.1 |
| pH                          | 7.3 ± 0.1        | 7.2 ± 0.1            | 0.03 |
| WBC (×10^3/mm^3)            | 14,000 ± 7,000   | 14,000 ± 7,000       | NS |
| Hemoglobin (g/dL)           | 11 ± 3           | 10 ± 3               | NS |
| Platelets (×10^3/mm^3)      | 160 ± 120        | 120 ± 80             | NS |
In univariate analysis, the rate of use of mechanical ventilation was significantly higher for the non-survivor group than the survivor group (76% vs. 44%, respectively; $P=0.02$). Oliguria before the initiation of CVVHDF occurred significantly more often in the non-survivor group than in the survivor group (80% vs. 50%, respectively; $P=0.03$). The mean APACHE II score was significantly higher for the non-survivor group than for the survivor group (34 ± 7 vs. 29 ± 7, respectively; $P=0.01$), as well as the SOFA score (13 ± 4 vs. 11 ± 4, respectively; $P=0.03$).

Multivariate Cox proportional hazards analysis showed that a urine output < 500 mL for 12 hours before the initiation of CVVHDF was the only significant risk factor for 90-day mortality (odds ratio $=2.1$, confidence interval $=1.01$–$4.4$, $P=0.048$) (Table 3). Comorbidities, cause of shock, clinical severity scores, degree of metabolic acidosis, and type of anticoagulation were not found to contribute to the mortality rate.

### Discussion

This study shows that a decreased urine output < 500 mL for 12 hours before the initiation of CVVHDF, is an independent risk factor for 90-day mortality. This result suggests that early initiation of CVVHDF may be associated with improved survival and that a decrease in urine output could be a parameter used to determine the time of CVVHDF initiation in hemodynamically unstable patients.

Several previous trials have investigated the prognostic factors for mortality of patients undergoing CRRT; these studies found different prognostic factors [8,10,11]. One study showed that metabolic acidosis and earlier initiation of CRRT were associated with the survival of patients with AKI receiving CRRT [10]. In another study, the independent prognostic factor for mortality in AKI patients treated with CRRT was found to be the APACHE II score [7]. In the current study, univariate analysis showed that arterial pH and APACHE II score were significantly different between survivors and non-survivors. However, multivariate analysis did not show that these factors were significant predictors of mortality.

Boorman et al. [13] defined early hemofiltration as treatment started when urine output is decreased < 30 mL/hour for over 6 hours and reported that early dialysis did not affect mortality. Bae et al. [11] reported that lower mean arterial blood pressure and lower serum bicarbonate levels measured the day after CRRT may predict a poor prognosis. These conflicting results might be caused by differences in disease severity and study populations, because we examined prognostic factors in a group with more severe disease and hemodynamic instability.

Our study indicates that urine output may be an important parameter for the determination of the optimal time for CRRT. Fluctuations in blood pressure affect renal blood flow and GFR due to renal autoregulation [14]. A marked reduction in renal perfusion may overwhelm autoregulation and precipitate an acute fall in GFR.

After Bellomo et al. [12] first suggested the RIFLE criteria for the classification of the severity of AKI and patient prognosis, many attempts have been made to prove the usefulness of these criteria. Studies report that when CRRT is applied at the “injury stage” when severity is relatively low, the mortality of patients decreases [15–19]. In addition, a recent domestic study also showed that the 90-day mortality rate was significantly lower in patients who received CRRT in the injury stage of the RIFLE criteria, when compared with those in the failure or loss stages [20]. However, the current study showed that there was no difference in 90-day mortality between the RIFLE-I group and the RIFLE-F group. Our results suggest that starting treatment prior to the RIFLE-I stage may represent the optimal timing for CRRT. Further studies using the RIFLE criteria as a prognostic factor are needed to support this idea.

There are some limitations to our study. Firstly, it is a retrospective, observational, single-center study, with all the inherent limitations of such investigations. Further, our study could not rule out the selection bias included in variable clinical conditions and the size of the study group was relatively small. Therefore, further prospective, multiple-center, large-group studies will be needed to clarify the factors affecting prognosis in hemodynamically unstable AKI patients receiving CRRT.

In conclusion, a decreased urine output < 500 mL for 12 hours before the initiation of CVVHDF, is an independent prognostic factor for mortality in AKI patients with hemodynamic instability treated with CVVHDF. This result suggests that early initiation of CRRT before a decrease in urine output is beneficial.

### Conflict of interest

The authors declare there is no conflict of interest.

### References

[1] Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P: Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 359:7–20, 2008

[2] Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. *Am J Kidney Dis* 43:342–349, 2004

[3] Ronco C, Bellomo R: Dialysis in intensive care unit patients with acute kidney injury; continuous therapy is superior. *Clin J Am Soc Nephrol* 2:597–600, 2007

[4] Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. *Kidney Int* 60: 1154–1163, 2001

[5] Nele VDN, Francis V, Annemieke D, Francis C, Wim VB, Raymond V, Novert L: The dialytic management of acute renal failure in the elderly. *Semin Dial* 15:127–132, 2002

### Table 3. Multivariate Cox proportional hazards ratio of 90-day mortality after the initiation of continuous veno-venous hemodiafiltration (CVVHDF)

| Parameter | Odds ratio | 95% Confidence interval | $P$ |
|-----------|------------|-------------------------|-----|
| SOFA score | 1.1        | 0.99–1.18               | 0.1 |
| Urine output < 500 mL for 12 h before initiation of CVVHDF | 2.1 | 1.01–4.4 | 0.048 |

In Table 3, the data shows the odds ratio and confidence intervals for the parameters SOFA score and urine output before the initiation of CVVHDF, indicating a higher risk of 90-day mortality with these factors.
[6] John AK, Derek CA, John PJ, Martine LM, Nagarajan R, Walter TL: Continuous versus intermittent renal replacement therapy: a meta-analysis. *Intensive Care Med* 28:29–37, 2002

[7] Soubrier S, Leroy O, Devos P, Nseir S, Georques H, d’Escrivan T, Guery B: Epidemiology and prognostic factors of critically ill patients treated with hemodiafiltration. *J Crit Care* 21:66–72, 2006

[8] Kim ES, Ham YR, Jang WI, Jung JY, Kwon OK, Choi DE, Na KR, Lee KW, Shin YT: Prognostic factors of acute renal failure patients treated with continuous renal replacement therapy. *Korean J Nephrol* 29:54–63, 2010

[9] Gjyzaria A, Muzi L, Morabito S: Continuous renal replacement therapy for acute renal failure in critically ill patients and early predictive factors. *BANTAO Journal* 5:58–60, 2007

[10] Lee SH, Kwon SK, Kim HY: Outcome and prognosis in patients receiving continuous renal replacement therapy. *Korean J Nephrol* 29:434–440, 2010

[11] Bae WK, Lim DH, Jeong JM, Jung HY, Kim SK, Park JW, Bae EH, Ma SK, Kim SW, Kim NH, Choi KC: Continuous renal replacement therapy for the treatment of acute kidney injury. *Korean J Intern Med* 23:58–63, 2008

[12] Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, the ADQI workgroup: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 8:R204–R212, 2004

[13] Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J: Effects of high volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. *Crit Care Med* 30:2205–2211, 2002

[14] David GS, Giovambattista C, Robert JU: Renal physiology. In: Feehally J, Floege J, Johnson RJ, editors. *Comprehensive Clinical Nephrology*. 3rd edition. Philadelphia: Mosby Elservier; p. 13–26, 2007

[15] Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM: The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. *Am J Kidney Dis* 46:1038–1048, 2005

[16] Bagshaw SM, George C, Dinu I, Bellomo R: A multicentre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 23:1203–1210, 2008

[17] Bell M, Liljestam E, Granath F, Fryckstedt J, Ekborn A, Martling CR: Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. *Nephrol Dial Transplant* 20:354–360, 2005

[18] Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. *Crit Care* 10:R73, 2006

[19] Gibney N, Hoste E, Burdmann EA, Bunchman T, Kher V, Viswanathan R, Mehta RL, Ronco C: Timing of initiation and discontinuation of renal replacement therapy in AKI: unanswered key questions. *Clin J Am Soc Nephrol* 3:876–880, 2008

[20] Kim YC, Hwang JH, Cho EJ, Lee HJ, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim SG, Kim DK: Clinical parameters to determine the optimal timing of CRRT in critically ill patients with acute kidney injury. *Korean J Nephrol* 30:585–592, 2011